Stay updated with breaking news from Pharma Two. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's...
DelveInsight's analysts estimate that the Parkinson's disease market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies
BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.“In early Parkinson’s disease, there are many side effects associated with dopamine agonists, including excessive daytime sleepiness,
An experimental agent combines low-dose, extended-release formulations of two commercially available PD drugs with similar efficacy but with less daytime sleepiness and orthostatic hypotension.
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed...